Investigational drug · Phase 2
HCB101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Solid Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Feb 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "HCB101"
First trial start
2025
Mar 13, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HCB101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Cancer
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "HCB101" as an intervention, largest first.
- Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid TumorsActive, not recruiting
FBD Biologics LimitedIndustry
NCT06771622 · 500 participants (planned) · Start Mar 13, 2025 · Primary completion Jan 1, 2028
Drug: HCB101; Trastuzumab and 17 more · For: Solid Cancer
Sites: Jinan, China
FBD Biologics LimitedIndustry
NCT05892718 · 80 participants (planned) · Start Oct 2, 2023 · Primary completion May 30, 2027
Drug: HCB101 · For: Advanced Solid Tumor; Refractory Non-Hodgkin Lymphoma
Sites: Port Saint Lucie, Florida; Huntersville, North Carolina; Greenville, South Carolina · 8 sites in all
Taipei Veterans General Hospital, TaiwanGovernment (non-federal)
NCT07136545 · 50 participants (planned) · Start Aug 13, 2025 · Primary completion Dec 31, 2026
Drug: HCB101; Pembrolizumab · For: HNSCC
Sites: Taoyuan, Taiwan; Taipei, Taiwan · 3 sites in all
Chang Gung Memorial HospitalAcademic, hospital or other
NCT07204574 · 40 participants (planned) · Start May 14, 2025 · Primary completion Dec 31, 2025
Drug: HCB101; Bevacizumab and 3 more · For: CRC
Sites: Taoyuan, Taiwan
Kaohsiung Medical University Chung-Ho Memorial HospitalAcademic, hospital or other
NCT07680569 · 40 participants (planned) · Start Jun 2026 · Primary completion Dec 2027
Drug: Zolbetuximab; Oxaliplatin + 5-Fluorouracil/Leucovorin and 1 more · For: GC/GEJC
Newest research
PubMed records naming it or its code names, newest first.
- HCB101: a novel potent ligand-trap Fc-fusion protein targeting the CD47-SIRPα pathway with high safety and preclinical efficacy for hematological and solid tumors.
Wang JT, Tseng CL, Teng HF, et al. · J Hematol Oncol 2025
Also in development for Solid Cancer
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.